Gapping down
In reaction to strong earnings/guidance:
- MDCA -23.4%, HDSN -19%, NUAN -14.9%, SNR -13.5%, SPKE -12.2%, OTEX -10.2%, SAIL -7.9%, SYNA -7.4%, INFN -6.5%, BOLD -6.5%, KODK -6.4%, SND -6.4%, TGI -5.9%, FTK -5.5%, MELI -4.5%, BKNG -4.4%, AXDX -4.2%, IMMU -3.6%, IEA -3.6%, AYX -3.5%, NVAX -3.5%, LB -3.3%, PTCT -3.1%, TROX -2.8%, FTI -2.7%, BSTI -2.6%, SUN -2.1%, PBYI -2%, ATUS -1.7%, FNV -1.7%, RXII -1.5%, ELF -1.3%, AG -1.2%, NICE -1.2%
Other news:
- EXEL -29.2% (Partner Roche provides update on Phase III Study of TECENTRIQ and COTELLIC; did not meet its primary endpoint of overall survival)
- SNCR -16.1% (does not expect to regain compliance with the continued listing requirements set by the Nasdaq Hearings Panel prior to May 10)
- IART -7.1% (prices offering of 5,250,000 shares of common stock at $58.50 per share)
- NBR -4.5% (prices its offerings of 35,000,000 of its common shares at $7.75/share)
Analyst comments:
- M -4.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- MIDD -1.4% (downgraded to Neutral from Outperform at Robert W. Baird)
- COG -1% (downgraded to Underperform from Buy at BofA/Merrill)
![]()